Perampanel for Seizure Prevention Post-Craniotomy: A Randomized Trial
• A multi-center, randomized trial is underway in Japan to evaluate perampanel's efficacy in preventing early seizures after craniotomy for brain tumors.
• The trial includes patients aged 18-80 undergoing craniotomy for supratentorial brain tumors and assesses seizure incidence within 28 days post-surgery.
• Patients will be randomized to receive perampanel or standard care, with comprehensive monitoring for adverse events and adherence to the treatment protocol.
• The study aims to determine if perampanel reduces postoperative seizure incidence, length of hospital stay, and other complications compared to the control group.
Olomorasib Plus Pembrolizumab Shows Promise in KRAS G12C-Mutated NSCLC
• Olomorasib combined with pembrolizumab demonstrated a 77% overall response rate in first-line NSCLC patients with KRAS G12C mutations, regardless of PD-L1 expression.
• In previously treated NSCLC patients, the combination therapy achieved a 40% overall response rate and an 88% disease control rate.
• Common adverse events included diarrhea, fatigue, and increased ALT levels, with manageable safety profiles observed across both cohorts.
• A global registrational trial, SUNRAY-01 (NCT06119581), is underway to further evaluate the combination in first-line KRAS G12C-mutated NSCLC.
© Copyright 2025. All Rights Reserved by MedPath